18th EBF Open Symposium

18 - 20 November, 2025

Barcelona, Spain

Visit us at BOOTH 3C

Request a meeting with our on-site team to learn how we help our clients advance their therapeutic drug programs.

BioAgilytix will be presenting...

Janett Schwarz (2)
Challenges and Successes in Total Target Biomarker Assay Establishment  
Janett Schwarz, PhD 
Scientific Operations 
Tuesday, 18 November  
12:30 - 12:50  
Session 3: The wonderful world of NBE – applications 

Ellen Gattkowski (1) (2)
Bridging PK Reference Standards Across Global Bioanalytical Studies: Strategies and Lessons Learned
Ellen Gattkowski, PhD 
Scientific Operations
Wednesday, 19 November 
11:20 – 13:00 
Workshop 3: Kits and reagent bridging 

Lynn_Kamen_22D7421_Web (2)
To NAb or not to NAb: Is a stand-alone NAb assay required for your program?  
Subtitle: Presented by Lynn Kamen on behalf of the NAb Team in the AAPS BioAnalytical Community 
 Lynn Kamen, PhD 
Scientific Officer 
Wednesday, 19 November 
10:20 – 10:40 
Session 11: General ADA/Nab 

Dave_Beyerlein (2)
Insights into the development and validation of a total LC/MS approach for a PK assay for an ADC
Dave Beyerlein
Scientific Operations 
Wednesday, 19 November 
12:20 – 12:40 
Session 13: ADC 

TimSchau_headshot-foto
Re-evaluating the 3-Tier ADA Paradigm: A Case Study Supporting a 1-Tier Signal-to-Noise Ratio (SNR)-Based Strategy for Low-Risk Biotherapeutics 
 Tim Schauer, PhD 
Scientific Operations 
Thursday, 20 November 
11:50 – 12:10 
Session 19: 1-Tier Tech 

LauravonBerg
Evaluation of a 1-Tiered Versus 3-Tiered Approach in ADA Assay Validation and Application in a Clinical Phase I Study  
 Laura von Berg, PhD
Scientific Operations 
Thursday, 20 November 
15:00 – 15:20  
Session 21: 1-Tier: Strategic discussions 

Marco Klinge at BioAgilytix
POSTER PRESENTATION
TAb or NAb? Evaluating Assay Strategies for AAV Gene Therapy Patient Screening 
 Marco Klinge, PhD
Scientific Operations 

Poster times: 

Tuesday, 18 November from 12:50 – 14:00 + 15:40 – 16:20 

Wednesday, 19 November from 10:40 – 11:20, 13:00 – 14:00 + 15:40 – 16:20 

Thursday, 20 November from 10:20 – 11:10 + 12:50 – 14:00

Customized approaches to support your bioanalytical needs

BioAgilytix is the trusted partner for global bioanalytical services throughout every phase of the drug development process. We provide custom, fit-for-purpose, and comprehensive bioanalytical support for your program needs. We offer the complete package of pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing in a GxP environment. Our lab services include immunoassay, cell-based assay, molecular biology, and LC/MS assay development, validation, and sample testing, eliminating the need for multiple providers, ensuring efficient data delivery for your therapeutic study.  

Schedule a meeting with our experts on site

Learn how the combination of world-class scientific expertise, outstanding project management, and key regulatory insight can streamline our support for your therapeutic.

About the event 

EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. Its goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and regulatory issues in Bioanalysis. Until 2010, EBF membership was limited to pharmaceutical R&D companies with bioanalytical activities in Europe. From 2011 onwards, the EBF welcomed CROs having regulated BioA lab-activities in Europe. In 2010, the EBF registered as a non-profit organization (vzw) (the Belgian Act of 27 June 1921 on non-profit associations, international non-profit associations and foundations. The EBF non-profit organization was integrated into the Belgian Code on Companies and Associations (the BCCA) in 2023.   

Learn more about this event on their website

Barcelona, Spain

 

Schedule a meeting with our experts on site

Learn how the combination of world-class scientific expertise, outstanding project management, and key regulatory insight can streamline our support for your therapeutic.